Development and validation of an epigenetic biomarker that predicts treatment success and allows personalized management in rheumatoid arthritis and psoriasis

Development and validation of an epigenetic biomarker that predicts treatment success and allows personalized management in rheumatoid arthritis and psoriasis - EPIPSORA

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON56905

Enrollment

120

Registered

2023-12-22

Start date

2024-10-22

Completion date

Unknown

Last updated

2025-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis and rheumatoid arthritis (rheumatoid) psoriasis and rheumatoid arthritis (rheumatoid)

Interventions

N.v.t.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Diagnosis of rheumatoid arthritis or psoriasis - Active symptomatic disease - Indication for biologic treatment with adalimumab (both), tocilizumab (RA), abatacept (RA), ustekinumab (PsO) or secukinumab (PsO)

Exclusion criteria

Exclusion criteria: - Any condition which, in the opinion of the investigator, may interfere with  the patient's ability to comply with study procedures

Design outcomes

Primary

Measure	Time frame
Clinical efficacy will be measured according to routine care. Percentage of patients meeting established and validated endpoints for good treatment response: clinical disease activity index (CDAI) =50% at Week 12 for RA and Absolute Psoriasis Area and Severity Index (PASI) score	—

Secondary

Measure	Time frame
Not applicable.	—

Countries

Belgium, Netherlands, Portugal

Contacts

Public ContactM.G.H. Sande

Amsterdam UMC

m.g.vandesande@amsterdamumc.nl020-5662694

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)